In patients with Alzheimer’s disease, cholinesterase inhibitors limit the cognitive deficits early in the course of the disease, but dosing and efficacy are limited by cholinergic (in particular muscarinic) side effects. The gene discussed is BCHE; the disease is Alzheimer disease.